The director of the Fogarty Institute, medtech legend Dr. Tom Fogarty, shoots off some fireworks at MassMEDIC's 18th annual Medtech Showcase.
In the 50 years since Dr. Tom Fogarty invented the catheter-based treatment for blood clots that's now the standard of care, he's founded more than 30 medical device startups, placing him among the most prolific inventors in the biomedical space.
Forgarty is also, without a doubt, the industry's best quote.
Medtronic inks a package of loans worth more than $16 billion to back its $43 billion acquisition of Covidien.
Covidien's recall of its Puritan 980 ventilator over a software glitch earns Class I status from the FDA, the watchdog agency's highest-level alert.
Instead of quashing mergers and acquisitions altogether, the U.S. Treasury Dept.'s proposal on tax inversions may pull dealmaking onshore.
(Reuters) - Investors and bankers have been lamenting the potential death of large cross-border healthcare mergers since the U.S. Treasury Dept. announced in late September that it would curtail the tax breaks from international deals designed to give U.S. companies a legal home in a low-tax country.
Atherectomy and balloon angioplasty proves more effective than angioplasty alone in treating peripheral artery disease, according to new data from a Covidien study.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Medtronic unveils post-merger management structure; Abbott buys into electrophysiology with $250m Topera acquisition; Zimmer reveals post-Biomet merger plans; Medtronic, Covidien merger expected to close in 2015; Covidien deals Stellarex balloon to Spectranetics for $30m
Covidien's fiscal 4th-quarter and 2014 earnings top expectations on Wall Street as 4th-quarter profits soar 39%.
Covidien (NYSE:COV) handily beat analysts' expectations for its fiscal 4th-quarter and full-year results this morning, topping earnings-per-share forecasts with Q4 profit growth of 39%.